Developing a life-saving therapy is a journey marked by breakthroughs and bottlenecks. Among the most challenging steps is scaleup—when a process that thrives in a laboratory flask must perform flawlessly in a 2,000-liter bioreactor. Variability can creep in, productivity may falter, and regulatory compliance becomes more complex. For biopharmaceutical developers, these challenges jeopardize timelines and delay the hope of treatments reaching patients. Ajinomoto CELLiST Korea exists to eliminate those uncertainties. “Our mission is to deliver more than just media. We deliver confidence that therapies can progress from concept to commercial production while maintaining uncompromised quality and reliability,” says Dr. Masakazu Sugiyama, president. From its headquarters in Songdo, Incheon—one of Asia’s leading bio-clusters—Ajinomoto CELLiST Korea anchors its strategy on a clear identity. Its mission is to contribute to medical advancement and better lives by providing cell culture media. Its vision is to become Asia’s most preferred and trusted cell culture media supplier. And its values are rooted in a customer-centered culture, operational excellence, and the promise of stable, speedy, and superb quality. This foundation ensures that every decision, from scientific innovation to customer partnership, aligns with long-term trust and reliability. Bridging Asia and the Global Biopharmaceutical Market What sets Ajinomoto CELLiST Korea apart is its dual positioning: deeply rooted in Asia while seamlessly connected to the global biopharmaceutical ecosystem. As part of the Ajinomoto Group—a company with a long history in biotechnology and amino acid science leadership—Ajinomoto CELLiST Korea leverages global expertise while tailoring solutions to regional growth trends. Asia’s demand for advanced therapies is expanding rapidly. By supporting both multinational firms and regional champions, Ajinomoto CELLiST Korea acts as a strategic bridge, enabling the globalization of biopharmaceutical manufacturing and accelerating the path of therapies from Asia to the world. Ajinomoto’s long-standing AminoScience heritage gives Ajinomoto CELLiST Korea a unique edge in designing highly optimized media formulations. This expertise extends beyond antibody manufacturing into next-generation modalities such as vaccines, cell therapies, and gene therapies. This breadth reflects not only scientific ingenuity but also a commitment to enabling the therapies of tomorrow. Each formulation is designed with scalability, sustainability, and regulatory readiness in mind..

Bringing medical devices and drugs from R&D labs to patients demands precision at every step. Accuracy in language is crucial to guarantee that scientific data, regulatory submissions and clinical documentation are correctly conveyed. A single misstep can lead to costly delays, regulatory setbacks and safety risks. Regulus Pharma Services is a trusted partner for pharmaceutical companies, biotech innovators and medical device manufacturers seeking precise, reliable translation services for global regulatory processes. From investigational drug brochures, clinical trial protocols and standard technical documents to package inserts, inquiries and biotechnology documents, Regulus Pharma ensures that complex science is translated into clear, compliant communication. In an industry where every word can make or break a breakthrough, Regulus Pharma is the silent force helping innovation reach the world. “Our mission has always been to provide consistent, best-quality translation services to help our clients seamlessly navigate the development and regulatory processes,” says Katsuo Hoshi, representative director. Regulus Pharma began as a general technical translation agency, assisting industries with translating export manuals and consumer product documentation. Later, a pivotal partnership with a bilingual Japanese-American physician shifted the organization’s focus to the medical, pharmaceutical and biotechnology sectors. Over the years, Regulus Pharma has evolved alongside industry demands. Today, it focuses on regulatory science, providing translation services at every stage of drug and medical device development. These include preclinical studies, clinical trials, new drug applications, consultations with regulatory authorities and post-approval activities, and post-marketing surveillance. Minimizing Errors, Maximizing Consistency A key element of Regulus Pharma’s strength is its carefully curated network of expert translators. Each translator brings extensive experience in medical and pharmaceutical translation, and many hold advanced academic degrees, including Ph.Ds in medical science..